Photocure ASA
OSL:PHO ISIN:NO0010000045
News
Photocure ASA Oslo, Norway, 27 June 2008: Photocure ASA announces today that Metvixia(TM) in combination with Aktilite® CL128, the LED based narrow band (630 nm) red light technology device has been approved by US Food and Drug Administration (FDA) for the treatment of actinic keratosis (AK), a pre-cancerous skin lesion.
Photocure ASA Oslo, 10 June 2008 - PCI Biotech Holding ASA, the Norwegian drug delivery company with a focus on cancer therapeutics, today announced the successful closing of its initial public offering in connection with the listing of the PCI Biotech Holding ASA shares on Oslo Axess (the Share Issue). The offering price was NOK 20 per share. Gross proceeds amounted to NOK 60 million (Approximately USD 11.9 million). PCI Biotech Holding ASA shares are expected to begin trading on the Oslo Axess (ticker: PCIB) on Wednesday 18 June 2008.
3,392 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 13) (Last 30 Days: 36) (Since Published: 3392)